Abstract 205TiP
Background
The combination of atezolizumab (Atezo) and bevacizumab (Bev) is recommended as a first-line treatment for unresectable HCC (uHCC) in the Japanese guidelines for liver cancer treatment, as well as in the guidelines of the Barcelona Clinic Liver Cancer (BCLC) Group and the American Association for the Study of Liver Diseases, based on the results of the IMbrave150 trial. In the subgroup analysis of the IMbrave150 trial, patients with stable disease (SD), accounting for approximately 40% of the total population, had statistically significantly shorter overall survival (OS) compared to patients with complete response (CR) or partial response (PR) (SD: median 17.1 months, CR+PR: median not reached, P<0.0001). Prolonging the prognosis of the SD group is one of the unmet medical needs for uHCC. On the other hand, transcatheter arterial chemoembolization (TACE) could achieve a high local effect and control intrahepatic lesions. In addition, TACE has been reported to activate anti-tumor immunity and therefore, might synergistically enhance the efficacy of Atezo plus Bev.
Trial design
This is a multicenter, phase III study of patients with uHCC who have BCLC-B stage (including a single tumor with a diameter ≥5 cm) or BCLC-C stage (excluding Vp3 or 4) and Child-Pugh A liver function. Cohorts will be divided based on imaging evaluation at 12 weeks after Atezo plus Bev treatment. Patients with SD (RECIST ver.1.1) will be randomized (randomized cohort) to receive Atezo plus Bev with or without TACE (1:1 allocation) to investigate its contribution to extending OS (primary endpoint). In addition, patients with CR or PR based on imaging evaluation at 12 weeks after Atezo plus Bev treatment (ABC-conversion cohort) will be prospectively followed to evaluate the conversion rate (primary endpoint) and the prognosis of patients who receive conversion therapy.
Clinical trial identification
jRCT:s051230037.
Legal entity responsible for the study
The authors.
Funding
Chugai Pharmaceutical Co., Ltd.
Disclosure
T. Yamashita: Financial Interests, Personal, Invited Speaker: Eisai, Chugai, Lilly, Bayer, Takeda; Financial Interests, Institutional, Local PI: Bristol-Myers, MSD, Ono, Abbie, Eisai; Financial Interests, Institutional, Other, Sub-PI: Chugai. Y. Inaba: Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Advisory Board: AstraZeneca, Chugai; Financial Interests, Institutional, Local PI: Eisai, AstraZeneca, Chugai. M. Ikeda: Financial Interests, Personal, Advisory Board: AstraZeneca, Chugai, Eli Lilly Japan, Eisai, NIHON Servier, Novartis, MSD; Financial Interests, Personal, Invited Speaker: AstraZeneca, Bristol Myers Squibb, Chugai, Eli Lilly Japan, Eisai, NIHON Servier, Novartis, Taiho, Yakult, Teijin Pharma, AbbVie, Abbott Japan, Fujifilm Toyama Chemical, Incyte Biosciences Japan, Takeda, Ono, MSD, Taisho Pharmaceutical, Nippon Kayaku, Guardant Health Japan; Financial Interests, Institutional, Coordinating PI: Bayer, Bristol Myers Squibb, Eisai, AstraZeneca, Eli Lilly Japan, Chugai Pharmaceutical, MSD, Ono, Novartis, J-Pharma, Pfizer, Chiome Bioscience, NIHON Servier, Delta-Fly Pharma, Syneos Health, Merus.N.V., Merck biopharma, Boehringer Ingelheim, Invitae; Financial Interests, Personal, Steering Committee Member: Chugai, NIHON Servier, Takeda, Novartis, Eisai, Rakuten Medical. M. Sone: Financial Interests, Personal, Invited Speaker: Covidien Japan, Cardinal Health, AstraZeneca, CANON Medical Systems, Guerbet; Financial Interests, Personal, Advisory Board: Boston Scientific; Financial Interests, Institutional, Research Grant: CANON Medical Systems, Dream Medical Partners; Non-Financial Interests, Personal, Member: ASCO. K. Tsuchiya: Financial Interests, Personal, Invited Speaker: Chugai, Eisai, Takeda, AstraZeneca; Financial Interests, Personal, Advisory Board: Chugai. T. Tada: Financial Interests, Personal, Invited Speaker: Eisai, AbbVie, Chugai. T. Kodama: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co, AstraZeneca, Eisai Co.Ltd, Takeda pharmaceutical Co, AbbVie, Gilead Sciences. T. Kuzuya: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co. S. Ogasawara: Financial Interests, Personal, Advisory Board: AstraZeneca, Chugai, Eisai; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Funding: Chugai; Financial Interests, Personal, Research Grant: Eisai. M. Ueno: Financial Interests, Personal, Invited Speaker: AstraZeneca, Chugai Pharmaceutical, Incyte, MSD, Nihon Servier, Ono Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical; Financial Interests, Personal, Advisory Board: Nippon Boehringer Ingelheim, Novartis; Financial Interests, Institutional, Local PI: Astellas Pharma, AstraZeneca, Chugai Pharmaceutical, DFP, Daiichi Sankyo, Eisai, Incyte, MSD, Merck Biopharma, Ono Pharmaceutical, Taiho Pharmaceutical, Novartis. M. Moriguchi: Financial Interests, Personal, Invited Speaker: Eisai Co., Ltd., Bayer Yakuhin, Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Takeda Pharmaceutical Company Limited; Financial Interests, Personal, Advisory Board: Eisai Co., Ltd., Bayer Yakuhin, Ltd., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., AztraZeneca K.K.; Financial Interests, Institutional, Funding: MSD K.K. Eisai Co., Ltd., Bristol Myers Squibb K.K., Bayer Yakuhin, Ltd., Eisai Co., Ltd. K. Ueshima: Financial Interests, Personal, Invited Speaker, Concurrent roles with an advisory board: Chugai, Eisai, Takeda, Lilly Japan; Financial Interests, Personal, Invited Speaker: AstraZeneca, Otsuka, Taiho, Sumitomo, MSD, Kowa, EA pharma, AbbVie, Aska; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Local PI: Chugai. T. Takehara: Financial Interests, Personal, Invited Speaker: Chugai; Financial Interests, Institutional, Research Grant: Chugai. T. Hamano: Financial Interests, Personal, Invited Speaker: Chugai pharmaceutical co. ltd.; Financial Interests, Institutional, Officer: P4 statistics co. ltd.; Financial Interests, Personal, Stocks/Shares: P4 statistics co. ltd. M. Kudo: Financial Interests, Personal, Invited Speaker: Eisai, Chugai, Eli Liiy, Bayer, Takeda, AstraZeneca; Financial Interests, Institutional, Research Grant: Otsuka, EA Pharma, Taiho, Eisai, AbbVie, GE Healthcare, Chugai. All other authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract